Ozempic vs Wegovy vs Zepbound

Ozempic and Wegovy contain semaglutide, a GLP-1 receptor agonist. Zepbound contains tirzepatide, which activates both GIP and GLP-1 receptors. That ingredient difference means a price quote, prescription or study involving one product cannot automatically be applied to another.

Semaglutide appears under multiple brand names because the FDA approves specific products, formulations and labels—not an ingredient as one universal treatment. Ozempic and Wegovy therefore share an ingredient while differing in approved uses, available strengths and delivery options. Their labels also say that combining them with other semaglutide products or GLP-1 receptor agonists is not recommended.

Brand names matter when reviewing an online offer. “Semaglutide” alone does not identify whether the offer is for FDA-approved Ozempic, FDA-approved Wegovy or a compounded product. The FDA states that compounded drugs are not FDA-approved and has warned against marketing them as generic or identical versions of approved GLP-1 products.

Ozempic is primarily a type 2 diabetes product. Its injection is approved to improve glycemic control in adults with type 2 diabetes, reduce major cardiovascular events in adults with type 2 diabetes and established cardiovascular disease, and reduce specified kidney and cardiovascular outcomes in adults with type 2 diabetes and chronic kidney disease. Ozempic tablets are approved for glycemic control and for reducing major cardiovascular events in adults with type 2 diabetes who are at high risk. Neither Ozempic label lists chronic weight management as an approved use.

Wegovy is approved for long-term weight reduction in eligible adults with obesity or overweight; the injection is also approved for adolescents age 12 and older with obesity. Both the injection and tablets have an indication to reduce major cardiovascular events in adults with established cardiovascular disease and obesity or overweight. The injection additionally has an accelerated-approval indication for certain adults with noncirrhotic MASH and moderate-to-advanced liver fibrosis.

Zepbound is approved for long-term weight reduction in adults with obesity or adults with overweight plus at least one weight-related condition. It is also approved to treat moderate-to-severe obstructive sleep apnea in adults with obesity. Its current label does not include an indication for treating type 2 diabetes or reducing major cardiovascular events.

These distinctions matter because “helps with weight” and “FDA-approved for chronic weight management” are not equivalent claims. Compare the exact product, formulation and labeled indication being offered.

The current Ozempic labels cover once-weekly injections and once-daily tablets. Injection presentations include single-patient-use multidose pens and certain single-dose prefilled syringes. The tablets come in 1.5 mg, 4 mg and 9 mg strengths. The tablet and injection labels provide separate administration and switching instructions; their milligram numbers should not be treated as direct equivalents.

Wegovy is also available as a once-weekly injection and a once-daily tablet. Its injection presentations include single-dose pens and syringes, a single-patient-use multidose pen and Wegovy HD. Tablets are available in 1.5 mg, 4 mg, 9 mg and 25 mg strengths. Some Wegovy indications are formulation-specific: for example, the MASH and adolescent weight-management indications appear on the injection label, not the tablet indication section.

Zepbound remains injection-only under the current label. Presentations include single-dose pens, single-dose vials, multidose vials and a four-dose, single-patient-use KwikPen. An offer should identify the device because supplies and handling differ: LillyDirect states that KwikPen purchases require pen needles, while vial purchases require needles and syringes. Device preference is a practical comparison point, but it does not determine which medicine is clinically appropriate.

All three products carry an FDA boxed warning about thyroid C-cell tumors observed in rodents. The labels state that it is unknown whether semaglutide or tirzepatide causes these tumors, including medullary thyroid carcinoma, in humans. Each product is contraindicated for people with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2.

Their labels also warn about acute pancreatitis and acute gallbladder disease. Pancreatitis has been observed with GLP-1 receptor agonists or the products themselves, while gallstones or gallbladder inflammation have occurred or been reported in clinical trials. Severe gastrointestinal reactions, kidney injury related to volume depletion, serious hypersensitivity reactions and possible complications around anesthesia or deep sedation also appear in current labeling.

The overlap does not make the safety profiles identical. Ozempic includes diabetes-specific concerns such as diabetic retinopathy complications and hypoglycemia risk when used with insulin or an insulin secretagogue. Zepbound has a specific warning that it can affect oral contraceptive effectiveness after treatment begins and after dose increases. A useful clinician conversation should cover personal and family thyroid history, prior pancreatitis or gallbladder disease, current diabetes medicines, planned procedures, pregnancy considerations and every oral medication being taken.

Insurance and cash prices answer different questions. An insurer may evaluate the exact brand, formulation, labeled use and prior-authorization criteria. A low cash quote also may be processed outside insurance, meaning the payment does not count toward a deductible or insurance out-of-pocket maximum. Ask for the full recurring cost rather than relying on an introductory figure.

As of July 2026, NovoCare lists introductory self-pay pricing of $199 per month for the first two eligible fills of certain Ozempic injection strengths, followed by standard prices of $349 for the lower pen strengths and $499 for the 2 mg pen. Ozempic tablet cash prices vary by strength, starting at $149 per 30-tablet bottle. For Wegovy, NovoCare lists introductory injection pricing of $199 for two eligible fills, followed by $349 for standard injection strengths and $399 for Wegovy HD; tablet pricing starts at $149. Eligibility, deadlines and prices can change.

As of July 2026, LillyDirect lists Zepbound KwikPen and vial self-pay prices from $299 to $449 per 28-day supply. The $449 price for higher strengths depends on refilling within 45 days; otherwise, Lilly lists regular prices as high as $699. Program terms can be changed or ended.

Use NovoCare and LillyDirect as the canonical starting points for manufacturer cash-price comparisons, then confirm the exact form, recurring price, eligibility rules and insurance treatment. Direct medication and health decisions to a licensed clinician.

Ozempic and Wegovy both contain semaglutide, but the label, dose schedule and approved-use language differ. Ozempic's FDA label is built around type 2 diabetes uses and related risk-reduction language. Wegovy's label is built around chronic weight management, cardiovascular risk-reduction language for selected adults and other current label details. Zepbound is different again because it contains tirzepatide, a GIP/GLP-1 receptor agonist, and has its own prescribing information.

If the question is chronic weight management, Wegovy and Zepbound are the cleaner starting points because their official labels include weight-management uses. Ozempic may still appear in provider conversations, but for weight loss that usually means off-label prescribing. Off-label use is a clinician decision, not a marketing shortcut, and it should come with clear explanation of risks, alternatives and monitoring.

All three products have prescribing information that clinicians use to screen for contraindications, warnings, drug interactions and adverse reactions. Cost comparisons also need precision: insurance may treat diabetes and obesity indications differently, and cash-pay pricing can differ by product, dose, pharmacy and savings program. The safest consumer workflow is to confirm the exact brand, active ingredient, indication and total out-of-pocket cost before paying a provider.